These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 20855362)

  • 21. The Effect and Safety of 5-HT
    Gu P; Chen C; Wu Q; Dong C; Wang T; Wan Q; Dong X
    Biomed Res Int; 2021; 2021():6663591. PubMed ID: 34660796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted 5-HT
    Vila-Pueyo M
    Neurotherapeutics; 2018 Apr; 15(2):291-303. PubMed ID: 29488143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lasmiditan mechanism of action - review of a selective 5-HT
    Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
    J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?
    Neeb L; Meents J; Reuter U
    Neurotherapeutics; 2010 Apr; 7(2):176-82. PubMed ID: 20430316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lasmiditan Is a New Option for Acute Migraine Treatment.
    Blakely KK; Stallworth K
    Nurs Womens Health; 2020 Aug; 24(4):294-299. PubMed ID: 32663443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-Hydroxytryptamine receptor subtypes and the pharmacology of migraine.
    Peroutka SJ
    Neurology; 1993 Jun; 43(6 Suppl 3):S34-8. PubMed ID: 8389009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lasmiditan for acute treatment of migraine.
    Parikh S
    Drugs Today (Barc); 2021 Feb; 57(2):89-100. PubMed ID: 33656015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study).
    Brandes JL; Klise S; Krege JH; Case M; Khanna R; Vasudeva R; Raskin J; Pearlman EM; Kudrow D
    Cephalalgia; 2019 Oct; 39(11):1343-1357. PubMed ID: 31433669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs.
    Ramírez Rosas MB; Labruijere S; Villalón CM; Maassen Vandenbrink A
    Expert Opin Pharmacother; 2013 Aug; 14(12):1599-610. PubMed ID: 23815106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-HT1F receptor agonists in acute migraine treatment: a hypothesis.
    Ramadan NM; Skljarevski V; Phebus LA; Johnson KW
    Cephalalgia; 2003 Oct; 23(8):776-85. PubMed ID: 14510923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is selective 5-HT
    Rubio-Beltrán E; Labastida-Ramírez A; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2018 Jun; 186():88-97. PubMed ID: 29352859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecule of the month. Lasmiditan hydrochloride.
    Drug News Perspect; 2010 Sep; 23(7):455. PubMed ID: 20862397
    [No Abstract]   [Full Text] [Related]  

  • 33. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs.
    Tfelt-Hansen PC; Pihl T; Hougaard A; Mitsikostas DD
    Expert Opin Investig Drugs; 2014 Mar; 23(3):375-85. PubMed ID: 24289494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy.
    Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR
    Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.
    Lipton RB; Lombard L; Ruff DD; Krege JH; Loo LS; Buchanan A; Melby TE; Buse DC
    J Headache Pain; 2020 Feb; 21(1):20. PubMed ID: 32093628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists.
    Hougaard A; Tfelt-Hansen P
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1409-18. PubMed ID: 26095133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Present and future of 5-HT receptor agonists as antimigraine drugs.
    Pauwels PJ; John GW
    Clin Neuropharmacol; 1999; 22(3):123-36. PubMed ID: 10367177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The selective 5-HT
    Vila-Pueyo M; Page K; Murdock PR; Loraine HJ; Woodrooffe AJ; Johnson KW; Goadsby PJ; Holland PR
    Br J Pharmacol; 2022 Feb; 179(3):358-370. PubMed ID: 34600443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lasmiditan: First Approval.
    Lamb YN
    Drugs; 2019 Dec; 79(18):1989-1996. PubMed ID: 31749059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls.
    Pearlman EM; Wilbraham D; Dennehy EB; Berg PH; Tsai M; Doty EG; Kay GG
    Hum Psychopharmacol; 2020 Sep; 35(5):e2732. PubMed ID: 32449213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.